Equine immunoglobulin fragment F(ab')
Antisera
COVID-19
F(ab’)(2)
Passive immunotherapy
SARS-CoV-2
Virus neutralization
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
08
11
2021
revised:
02
02
2022
accepted:
12
03
2022
pubmed:
21
3
2022
medline:
19
4
2022
entrez:
20
3
2022
Statut:
ppublish
Résumé
Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab')
Identifiants
pubmed: 35306171
pii: S1521-6616(22)00062-6
doi: 10.1016/j.clim.2022.108981
pmc: PMC8926440
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin Fab Fragments
0
Immunoglobulin Fragments
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108981Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Sci Rep. 2020 Nov 19;10(1):20220
pubmed: 33214620
Medicina (B Aires). 2020;80 Suppl 3:1-6
pubmed: 32658841
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Virol Sin. 2018 Apr;33(2):201-204
pubmed: 29541941
JAMA. 2021 Jan 19;325(3):221-222
pubmed: 33315069
Toxicon. 2018 May;146:151-175
pubmed: 29534892
Antiviral Res. 2017 Jan;137:125-130
pubmed: 27890674
Lancet Infect Dis. 2015 Mar;15(3):285-92
pubmed: 25662592
Am J Med. 1980 Oct;69(4):567-70
pubmed: 7191633
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
Antiviral Res. 2020 Oct;182:104868
pubmed: 32659292
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
Cell. 2021 Aug 5;184(16):4203-4219.e32
pubmed: 34242577
J Immunol Methods. 1998 Dec 1;221(1-2):35-41
pubmed: 9894896
Front Med (Lausanne). 2021 Sep 06;8:743325
pubmed: 34552950
EClinicalMedicine. 2021 Apr;34:100843
pubmed: 33870149
Transfusion. 2020 Dec;60(12):2938-2951
pubmed: 32935877
Biol Aujourdhui. 2010;204(1):87-91
pubmed: 20950580
NPJ Vaccines. 2017 Jul 10;2:19
pubmed: 29263875
Vox Sang. 2020 Aug;115(6):488-494
pubmed: 32240545
Br J Clin Pharmacol. 2016 Mar;81(3):446-52
pubmed: 26256124
Virus Res. 2021 Nov;305:198555
pubmed: 34487766
BMJ. 2020 Mar 26;368:m1256
pubmed: 32217555
iScience. 2021 Nov 19;24(11):103315
pubmed: 34723156
Front Med (Lausanne). 2021 Sep 06;8:735853
pubmed: 34552949
Lancet Reg Health West Pac. 2021 Oct;15:100276
pubmed: 34568853
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Rep. 2020 Jul 21;32(3):107918
pubmed: 32668215
Cell Rep. 2021 Jul 20;36(3):109415
pubmed: 34270919
Antiviral Res. 2020 Feb;174:104666
pubmed: 31760108
J Virol. 2019 Feb 19;93(5):
pubmed: 30541860
Toxicon. 2013 Dec 15;76:63-76
pubmed: 24055551
Sci Rep. 2017 Feb 03;7:41537
pubmed: 28155869
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
EBioMedicine. 2017 May;19:119-127
pubmed: 28408242
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
Clin Infect Dis. 2015 Aug 15;61(4):496-502
pubmed: 25904375
Acta Pharmacol Sin. 2005 Dec;26(12):1479-84
pubmed: 16297347
J Infect. 2020 Sep;81(3):e31-e32
pubmed: 32622905
J Clin Invest. 2020 Oct 1;130(10):5112-5114
pubmed: 32634126
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Sci Rep. 2021 May 10;11(1):9825
pubmed: 33972631